肺表面活性物质在新生儿重症肺炎治疗中的应用价值-东南大学学报医学版

肺表面活性物质在新生儿重症肺炎治疗中的应用价值

单位：徐州医学院, 江苏徐州 221002

分类号：R722.135

出版年·卷·期（页码）：2015·34·第六期（958-961）

摘要：

目的:评价肺表面活性物质(PS)治疗新生儿重症肺炎的有效性及安全性,监测肺表面活性蛋白B(SP-B)在新生儿重症肺炎治疗前后的变化.方法:将48例重症肺炎新生儿分为治疗组(23例)和常规组(25例).两组患儿均给予机械通气治疗.治疗组同时给予PS治疗,气管内给药.结果:治疗组的氧合指数(OI)明显低于常规组,动脉/肺泡氧分压比值(a/APO2)明显高于常规组,差异有统计学意义(P<0.05).治疗组氧暴露时间明显小于常规组, 差异有统计学意义(P<0.05).治疗组机械通气时间小于常规组,差异有统计学意义(P<0.05).治疗组血清中及支气管肺泡灌洗液中SP-B的水平均显著高于常规组.两组患儿均治愈出院,无死亡病例.结论:PS治疗新生儿重症肺炎是有效的和安全的,可促进内源性肺表面活性物质的生成.

Objective: To evaluate the efficacy and safety of pulmonary surfactant (PS) on severe neonatal pneumonia. Methods: 48 newborn patients were divided into two separate groups, i.e., experimental group and conventional group. Both groups of patients were treated with mechanical ventilation. The experimental group additionally got intratracheal PS at the same time. Results: After treatment, the oxygenation index (OI) of experimental group was significantly lower than that of the conventional group (P<0.05), and arterial / alveolar oxygen partial pressure ratio (a / APO2) was significantly higher than that of the conventional group (P<0.05). Oxygen exposure of experimental group was significantly less than that of the conventional group (P<0.05). Duration of ventilation in experimental group was significantly shorter than that of the conventional mechanical (P<0.05). SP-B level in serum and bronchoalveolar lavage fluid of experimental group was significantly higher than that of the conventional group (P<0.05). Both groups of newborn patients were cured, no death occurred. Conclusion: PS treating neonatal severe pneumonia is safe and effective, and using exogenous pulmonary surfactant as a therapy for severe neonatal pneumonia can promote the formation of endogenous pulmonary surfactant.

参考文献：

[1] 田世松.氨澳索注射液佐治新生儿肺炎105例疗效观察[J].工企医刊,2006,19(4):5-6.
[2] 陈玥,封志纯.肺表面活性蛋白的合成表达与新生儿肺疾病[J].新医学,2005,36(5):300-302 .
[3] 张雪梅,陈海龙.肺表面活性物质相关蛋白A在急性肺损伤时的作用[J].中国中西医结合外科杂志,2010,16(6):721-722.
[4] 谢正平,戴峰,蒋燕.小儿麻疹合并重症肺炎的影响血分析[J].东南大学学报:医学版,2013,32(4):441-446.
[5] RUBENFELD G D,HERRIDGE M S.Epidemiology and outcomes of acute lung injury[J].Chest,2007,131(2):554.
[6] SWARNAM K,SORAISHAM A S,SIVANANDAN S.Advances in the management of meconium aspiration syndrome[J].Int J Pediatr,2012,2012:ID359571.
[7] SWEET D G,CAMIELLI V,GREISEN G, et al.European consensus guide lines on the management of neonatal respiratory distress syndrome in preterm infants 2010 update[J].Neonatology,2010,97(4):402-417.
[8] 武志红,陈晓,孙梦思,等.机械通气下肺表面活性物质治疗新生儿重症肺炎合并衰竭[J].南昌大学学报:医学版,2012,52(6):72-75.
[9] 夏宁,叶巍岭,杨代秀,等.肺表面活性物质治疗新生儿肺内/肺外源性急性肺损伤研究[J].中国新生儿科杂志,2014,29(2):90-93.
[10] WU Y Z,SINGER M,THOURON F, et al.Effect of surfactant on pulmonary expression of type IIA PLA(2)in an animal model of acute lung injury[J].Am J Physiol-Lung Cell Mol Physiol,2002,282(4):L743-750.
[11] BRINKER K G,GARNER H,WRIGHT J R.Surfactant protein A modulates the differentiation of murine bone marrow derived dendritic cells[J].Am J Physiol Lung Cell Mol Physiol,2003,284:L232-L241.
[12] BORRON P J,MOSTAGHEL E A,DOYLE C, et al.Pulmonary surfactant proteins A and D directly suppress CD3⁺/CD4⁺cell function:evidence for two shared mechanisms[J].Immunol,2002,169:5844-5850.
[13] CASALS C,ARIAS D J,VALINO F ,et al.Surfactant strengthens the inhibitory effect of creactive protein on human lung macrophage cytokine release[J].Am J Physiol Lung Cell Mol Physiol,2003,284(3):L466-L472.
[14] CAO L.Regulation of activity of nuclear factor kappa B and activator protein-1 by nitric oxide, surfactant and glucocorticoids in alveolar macrophages from piglets with acute lung injury[J].Acta Pharmacol Sin, 2003,24(12):1316-1323.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录